MENU
INKT
Stock ticker: NASDAQ
PRICE
CHANGE
CAPITALIZATION
MiNK Therapeutics (INKT) Ownership - Who owns MiNK Therapeutics?
MiNK Therapeutics Inc is a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases... Show more
Profile
Industry
N/A
Address
149 Fifth Avenue
Phone
+1 212 994-8250
Employees
31
Web
https://www.minktherapeutics.com
Details
Group
Domestic Stock Funds
Category
Biotechnology
Capitalization
28.76M
P/E Ratio
N/A
Total Cash
4.58M
Projected Growth
N/A
Total Debt
4.92M
Revenue
N/A
Risk (Beta)
0.20
Dividend Yield
N/A
Total Cash/Share
1.15
Total Debt/Equity
N/A
Revenue/Share
null USD as % of share price
Fundamentals
INKT
Capitalization
28.8M
P/E Ratio
N/A
Risk (Beta)
0.20
Dividend Yield
N/A
Total Cash
4.58M
Total Cash/Share
1.15
Total Debt
4.93M
Total Debt/Equity
N/A
Projected Growth (PEG Ratio)
N/A
Revenue/Share (as % of the share price)
0%
Revenue
0
ROE
N/A
Book Value
-19.59M
P/B Ratio
N/A
Cash Flow
N/A
Earnings
-2.86
Average Daily Volume YTD
N/A
Common Shares Outstanding - Security Level
40
Current Ratio
0.72
Current Revenue Per Employee
N/A
Dividends Per Share - Security
N/A
EBITDA
-10.43M
Float
N/A
Float - Current
N/A
Gross Income Margin
N/A
Revenue To Assets
-209.96
Shares Held By Institutions
863K
Shares Outstanding - Current
3.97M
Total Liabilities
25.3M
Total Volume MTD
N/A
Value
-1
Gain YTD
4.032
View a ticker or compare two or three
VS
VS
Show more...
Ad is loading...
A.I.Advisor
published price charts
A.I. Advisor
published General Information
General Information
Industry Biotechnology
Profile
Fundamentals
Details
Industry
N/A
Address
149 Fifth Avenue
Phone
+1 212 994-8250
Employees
31
Web
https://www.minktherapeutics.com